Intravitreal bevacizumab (Avastin®) in proliferative diabetic retinopathy
| Autor: | Andrea Scupola, Paola Sasso, Cristina Maria Savastano, Lucia Ziccardi, Emilio Balestrazzi, Benedetto Falsini, Angelo Maria Minnella |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Adult
Male Vascular Endothelial Growth Factor A medicine.medical_specialty genetic structures Bevacizumab Angiogenesis Inhibitors Retinal Neovascularization Antibodies Monoclonal Humanized Panretinal photocoagulation Injections Recurrence medicine Humans Fluorescein Angiography Intravitreal bevacizumab Aged Diabetic Retinopathy medicine.diagnostic_test business.industry Antibodies Monoclonal General Medicine Diabetic retinopathy Middle Aged medicine.disease Fluorescein angiography eye diseases Vitreous Hemorrhage Surgery Vitreous Body Ophthalmology Retreatment Vitreous hemorrhage Female sense organs business After treatment Case series medicine.drug |
| Zdroj: | Acta Ophthalmologica. 86:683-687 |
| ISSN: | 1755-375X |
| DOI: | 10.1111/j.1600-0420.2007.01042.x |
| Popis: | Purpose: To evaluate the efficacy and safety of intravitreal bevacizumab in proliferative diabetic retinopathy (PDR) patients. Methods: This interventional case series study included 15 eyes of 10 patients with bilateral PDR: 13 eyes with severe PDR and active new vessels (NV) and two eyes with recurrent vitreous haemorrhages. Study eyes received a single intravitreal injection of 1.25 mg (0.05 ml) bevacizumab. All eyes were followed up for 3 months, and eight of them for 9 months. Reinjection was performed in three eyes 4–6 months after the first injection. Study eyes were evaluated by fluorescein angiography at baseline, 1, 3 and 9 months. Quantitative planimetric analysis (QPA) of NV area was measured before and after treatment. All eyes received or completed panretinal photocoagulation (PRP) 1 month after the first injection. Results: As early as at 1 month, all study eyes had a regression (paired t-test, P = 0.01) of QPA-estimated NV area. The eyes with recurrent vitreous haemorrhages had clearing of bleeding. These early effects were maintained at 3 months for all eyes and tended to be stable at 9 months. The fast and measurable efficacy of bevacizumab allowed a subsequent complete and safe PRP. Conclusion: Intravitreal bevacizumab did not reveal any side-effects and was effective in the regression of NV areas and the resolution of vitreous haemorrhages. This approach is potentially useful in allowing (within a planned temporal window) a safe and efficient PRP to be performed while minimizing the risk of its complications. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|